BioSpace News Archive

Phase 1 clinical study report for Voriconazole Inhalation Powder indicated no treatment emergent adverse events at peak plasma levels for Invasive Pulmonary Aspergillosis Phase 1 Single Ascending Dose study of Tacrolimus Inhalation Powder met and exceeded therapeutic drug levels with a single dose with no significant adverse events reported

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MYR GmbH for up to approximately €1.45 billion in aggregate cash consideration. The acquisition provides Gilead with Hepcludex ® (bulevirtide), which was conditionally approved by the European Medicines Agency for the treatment of chronic hepatitis delta virus (HDV) in adults

Olympus announced its 2021 support of major national colorectal cancer organizations and initiatives to increase screening and awareness, as part of National Colorectal Cancer Awareness Month, which is observed annually to educate the public on the importance of colorectal cancer prevention.

Turning Point Therapeutics, Inc., a precision oncology company developing next-generation therapies that target genetic drivers of cancer, announced its participation in the following investor conferences

Data Analysis Supports Use of Predictive Enrichment Markers in Phase 2b OraGrowtH210 Trial

Outlook Therapeutics, Inc. announced that Lawrence A. Kenyon, President, CEO and CFO of Outlook Therapeutics, will participate in a fireside chat at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.

Medtronic plc, the global leader in medical technology, announced the first procedures in the investigational device exemption pivotal trial to evaluate the PulseSelect™ Pulsed Field Ablation System, a novel, breakthrough technology that uses pulsed electric fields to treat atrial fibrillation.

AIkido Pharma Inc. (NASDAQ: AIKI) (“AIkido” or the “Company”) today announced it will be featured as a presenting company at the H.C. Wainwright Global Life Sciences Conference, a virtual conference held March 9-10, 2021.

Contentsquare, the leading experience analytics company, is partnering with leaders in the pharmaceutical and biotech sector to help manage the accelerated shift to digital healthcare.

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today provides an update on its business and product pipeline.